Erratum: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status (Acta Neuropathol (2012) 124 (547-560) DOI:10.1007/s00401-012-1016-2);MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

Acta Neuropathologica

Volumn 124, Issue 4, 2012, Pages 547-560

  Bady, Pierre ^a,b   Sciuscio, Davide ^a   Diserens, Annie Claire ^a   Bloch, Jocelyne ^a   Van Den Bent, Martin J ^c   Marosi, Christine ^d   Dietrich, Pierre Yves ^e   Weller, Michael ^f,g   Mariani, Luigi ^h   Heppner, Frank L ⁱ   Mcdonald, David R ^j   Lacombe, Denis ^k   Stupp, Roger ^a   Delorenzi, Mauro ^a,b,l   Hegi, Monika E ^a,l  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j UNIVERSITY OF WESTERN ONTARIO   (Canada)

^k EORTC DATA CENTER   (Belgium)

^l EPFL   (Switzerland)

more..

Author keywords

DNA methylation; Infinium methylation platform; MGMT; MSP; Prediction model

Indexed keywords

ALKYLATING AGENT; TEMOZOLOMIDE;

ACCURACY; ANALYZER; ANAPLASTIC CARCINOMA; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; CPG ISLAND; DISEASE ACTIVITY; DNA METHYLATION; EPIGENETICS; GENE; GENE EXPRESSION; GENE LOCATION; GENE SILENCING; GENETIC DATABASE; GLIOBLASTOMA; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MOLECULAR PROBE; O6 METHYLGUANINE DNA METHYLTRANSFERASE GENE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TREATMENT OUTCOME;

EID: 84866542816     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-013-1134-5     Document Type: Erratum

References (53)

1. Burnham KP, Anderson DR (2002) Model selection and multimodel inference: a practical information theoretic approach Springer-Verlag, New York
2. Collett D (2002) Modelling binary data Chapman & Hall/CRC, London
3. Criniere E, Kaloshi G, Laigle-Donadey F et al (2007) MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities J Neurooncol 83:173-179
4. Du P, Zhang X, Huang CC et al (2010) Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis BMC Bioinformatics 11:587
5. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343:1350-1354
6. Esteller M, Hamilton SR, Burger PC et al (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Res 59:793-797
7. Etcheverry A, Aubry M, de Tayrac M et al (2010) DNA methylation in glioblastoma: impact on gene expression and clinical outcome BMC Genomics 11:701
8. Everhard S, Tost J, El Abdalaoui H et al (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas Neuro Oncol 11:348-356
9. Faraway JJ (2006) Extending linear models with R: generalized linear, mixed effects and nonparametric regression models Chapman & Hall/CRC, Boca Raton
10. Felsberg J, Thon N, Eigenbrod S et al (2011) Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6, and PMS2 in paired primary and recurrent glioblastomas Int J Cancer 129:659-670
11. Figueroa ME, Abdel-Wahab O, Lu C et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18:553-567
12. Gilbert MR, Wang M, Aldape KD et al (2011) RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM) J Clin Oncol 29:suppl; abstr 2006
13. Harrell FE (2001) Regression modeling strategies, with applications to linear models, survival analysis and logistic regression Springer, New York
14. Harris LC, Potter PM, Tano K et al (1991) Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene Nucleic Acids Res 19:6163-6167
15. Hegi ME, Diserens AC, Godard S et al (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin Cancer Res 10:1871-1874
16. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352:997-1003
17. Hegi ME, Janzer RC, Lambiv WL et al (2012) Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC-26981/NCIC-CE.3 trial Acta Neuropathol 123:841-852
18. Hegi ME, Liu L, Herman JG et al (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity J Clin Oncol 26:4189-4199
19. Hinoue T, Weisenberger DJ, Lange CP et al (2012) Genomescale analysis of aberrant DNA methylation in colorectal cancer Genome Res 22:271-282
20. Hosmer DW, Lemeshow S (2000) Applied logistic regression Wiley Interscience, Chichester
21. Issa JP (2004) CpG island methylator phenotype in cancer Nat Rev Cancer 4:988-993
22. Lambiv WL, Vassallo I, Delorenzi M et al (2011) The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence Neuro Oncol 13:736-747
23. Malley DS, Hamoudi RA, Kocialkowski S et al (2011) A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts Acta Neuropathol 121:651-661
24. Malmstrom A, Grønberg BH, Marosi C et al (in press) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy for patients aged over 60 years with glioblastoma: the Nordic randomized phase 3 trial Lancet Oncol
25. McCullagh P, Nelder JA (1989) Generalized linear models Chapman & Hall/CRC, London
26. Murat A, Migliavacca E, Gorlia T et al (2008) Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma J Clin Oncol 26:3015-3024
27. Nakagawachi T, Soejima H, Urano T et al (2003) Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer Oncogene 22:8835-8844
28. Nelder JA, Wedderburn RWM (1972) Generalized linear models J Roy Stat Soc Ser A 135:370-384
29. Noushmehr H, Weisenberger DJ, Diefes K et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17:419-420
30. Ochs K, Kaina B (2000) Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent Cancer Res 60:5815-5824
31. Patefield WM (1981) Algorithm AS159 An efficient method of generating r x c tables with given row and column totals Appl Stat 30:91-97
32. R Development Core Team (2011) R: a language and environment for statistical computing Austria, Vienna
33. Reifenberger G, Hentschel B, Felsberg J et al (2011) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly Int J Cancer
34. Sciuscio D, Diserens AC, van Dommelen K et al (2011) Extent and patterns of MGMT promoter methylation in glioblastomaand respective glioblastoma-derived spheres Clin Cancer Res 17:255-266
35. Shah N, Lin B, Sibenaller Z et al (2011) Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM PLoS One 6:e16146
36. Stupp R, Dietrich P, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20:1375-1382
37. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10:459-466
38. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352:987-996
39. Stupp R, Van Den Bent MJ, Erridge SC et al (2010) Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC) J Clin Oncol 28:15s, (suppl; abstr TPS152)
40. The Cancer Genome Atlas Consortium (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455:1061-1068
41. Therneau TM, Grambsch PM (2000) Modeling survival data: Extending the cox model Springer, New York
42. Toyota M, Ahuja N, Ohe-Toyota M et al (1999) CpG island methylator phenotype in colorectal cancer Proc Natl Acad Sci USA 96:8681-8686
43. Turcan S, Rohle D, Goenka A et al (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Nature 483:479-483
44. van den Bent MJ, Dubbink HJ, Sanson M et al (2009) MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951 J Clin Oncol 9:5881-5886
45. van den Bent MJ, Gravendeel LA, Gorlia T et al (2011) A hypermethylated phenotype in anaplastic oligodendroglial brain tumors is a better predictor of survival than MGMT methylation in anaplastic oligodendroglioma: a report from EORTC study 26951 Clin Cancer Res 17:7148-7155
46. van Vlodrop IJ, Niessen HE, Derks S et al (2011) Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res 17:4225-4231
47. Venables WN, Ripley BD (2002) Modern applied statistics with S Springer, New York
48. Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17:98-110
49. Vlassenbroeck I, Califice S, Diserens AC et al (2008) Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma J Mol Diagn 10:332-337
50. Weller M, Stupp R, Reifenberger G et al (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6:39-51
51. Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J Clin Oncol 27:5874-5880
52. Wick W, Platten M, Meisner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Lancet Oncol
53. Zinn PO, Majadan B, Sathyan P et al (2011) Radiogenomic mapping of edema/cellular invasion MRI-henotypes in glioblastoma multiforme PLoS One 6:e25451